San Diego-based Viking Therapeutics marked itself as a serious competitor in the weight loss drug market place in February just after revealing promising details from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March the company unveil